Poor-Prognosis gestational trophoblastic disease: An update

Earl A. Surwit, David S. Alberts, C. D. Christian, Vivian E. Graham

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Ten patients with poor-prognosis gestational trophoblastic neoplasia were treated from 1979 to 1983 primarily with the modified Bagshawe chemotherapy regimen. Four patients were noted to have brain metastases, and one patient had liver metastases. In addition, etoposide (VP-16) was used in seven patients, bleomycin in six, cisplatin in five, 5-fluoro-uracil in two, and cis-retinoic acid in four patients. Thoracotomy, hysterectomy, and splenectomy were performed after chemotherapy was initiated for isolated resistant disease. At present, nine of the ten patients (90%) are in complete remission for four to 44 months. Significant myelosuppression was encountered in seven patients and life-threatening toxicity was noted in two patients. Currently, poor-prognosis patients are treated with the modified Bagshawe regimen, alternating every other week with etoposide, bleomycin, and cisplatin.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalObstetrics and gynecology
Issue number1
StatePublished - Jul 1984

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Poor-Prognosis gestational trophoblastic disease: An update'. Together they form a unique fingerprint.

Cite this